


Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer J Human Genet 47: 172-175


Increased Wnt signaling triggers oncogenic conversions of human breast epithelial cells by a Notch-dependent mechanism Proc Natl Acad Sci USA 102;13550-13555

AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene 21:3532–3540.


Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breast carcinomas. Histopathology. 56(7):876-82.

Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45:649–657.


Baylin SB, Herman JG (2000)
DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet;16;168


Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer 8:42.

Bellacosa A, Testa JR, Staal SP, Tsichilis PN (1991) 


Tyrosine kinase receptors as attractive targets of cancer therapy. Crit Rev Oncol Hematol 50:23-38


Allelic loss of chromosome is associated with tumor progression in breast carcinomas. Oncogene 17:123-127.

Brazil DP, Yang ZZ, Hemmins BA. (2004) 

A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin. Mol Cell Biol; 24:2986-2997
Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin.
Science 277:99-101


Carson C, Thoreen, David, Sabatini (2009)
Rapamycin inhibits mTORC1, but not completely. Autophagy, 5(5): 725-726.

Carnero A. (2010)
The PKB/AKT pathway in cancer Curr Pharm Des. 6(1):34-44.


Inactivation of the PTEN gene protein product is associated with the invasiveness and metastasis, but not angiogenesis, of breast cancer. Pathol Int 54(1):10-15.

Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Res. 7(4):R 394-401.

Citri A, Yarden Y (2006)

Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 59:1196-1201.


Creighton CJ (2007).
A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors Oncogene 26:4648–4655.


Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives Cancers 3:2478-2500.


mTOR and cancer therapy. Oncogene, 25: 6436-6446.


Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways.
Cancer Treat Rev. 38(6):698-707


Clinical significance of PTEN and p-AKT co-expression in HER-2 positive metastatic breast cancer patients treated with trastuzumab based therapies. Oncologu 78(2):141-149.


Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of protein kinase B/Akt-mediated survival-signaling. Radiotherapy and Oncology 80(2):199–206


The hallmarks of cancer. Cell 2000; 100:57


Upstream and downstream of mTOR. Genes Dev. 18:1926–1945.


Huang J, Dibble CC, Matsuzaki M, Manning BD. (2008)
The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol 28:4104-4115


Klaus Jurgen Schmitz, Friedrich Otterbach, Rainer Callies, Bodo Levkau, Melanie Hölscher, Oliver Hoffmann, Florian Grabellus, Rainer Kimmig, Kurt Werner Schmid and Hideo Andreas Baba (2004).

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22:3205–3212.

Knudson AG Jr. (1971)


Kumar CC, Madison V. (2005)
AKT crystal structure and AKT-specific inhibitors. Oncogene 24:7493–7501.

An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumoroverexpressing the c-erbB-2 (HER-2/neu) oncogene. Cancer Res 51:2593-2598.

Latta EK, Tjan S, Parkes RK, O'Malley FP (2002).
The Role of Her-2/neuOverexpression/Amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.15:1318-1325.
The expression of phospho-AKT1 and phospho-mTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas Modern Pathology 25:131–139.


Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol.Cell 10:457–468.


Lopez Knowles E., O Toole SA., McNeil CM., Millar EK., Qiu MR., Cre P., Daly RJ., Musgrove EA., Sutherland RI. (2010).
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 126(5):1121-1131.

Importance of race on breast cancer survival Ann surg Onco 4:80-87.


Maehama T., Dixon JE. (1998)

c-erbB-2 is not a major factor in the development of colorectal cancer Br J Cancer 86(4):568–573.


Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo and heterodimers. Mol Cell Biol 19:6845–6857

Evidence for PTEN-independent Akt activation and Akt-independent p27Kip1 expression in advanced bladder cancer. Oncology letters 2(6):1089-1093


Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells Invest New Drugs;29(5):752-9

Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445-1453

The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem;282:20329-20339.


erbB-2 and response to doxorubicin in patients with axillary lymph node- positive, hormone receptor-negative breast cancer. Journal of the National Cancer Institute 90(18) 1361–1370.


Proud CG (2009).


Rameh LE, Cantely LC(1999)
The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem 274:8347-8350

Reese D, Slamon DJ (1997).

GSK690693, a pan-AKT kinase inhibitor has potent anti-tumor activity and shows additive effect with lapatinib; AACR Meeting Abstracts; 14:279.

HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas: J Clin Pathol 60:1001-1005


Schlessinger J (2000)
Cell signaling by receptor tyrosine kinases. Cell 103:211-225


Altered transcription and expression of PTEN in breast tumors: is it regulated by hypermethylation? Breast Dis 33(1):27-33


P185, a product of the neu proto-oncogene, is a receptor-like protein associated with tyrosine kinase activity. Molecular and Cellular Biology 6(5):1729–1740


Tenorio GP, Stal O (2002).


Loss of PTEN expression followed by AKT phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocrine Related Cancer 10:203-208.


Tlsty TD, Hein PW (2001)
Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev 11: 54,


PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 11: 248


Willsher PC., Beaver J., Pinder S., Bell JA., Ellis IO., Blamey RW., Robertson JF. (1996)


Human epithelial growth factor receptor (Ile655Val) polymorphism and risk of breast fibroadenoma Eur J Cancer Prev 17(1):33-38